Mark Rothera Insider Profile

Mark Rothera, CCO at PTC Therapeutics, holds 100.00K shares in Viracta Therapeutics (Ticker: VIRX), holds 12.34K shares in PTC Therapeutics (Ticker: PTCT), holds 4.81K shares in Aegerion (Ticker: AEGR). Most recently, Mark Rothera Bought ― shares of Viracta Therapeutics on Dec 04, 2023 for an estimated value of 49.00K.
Mark Rothera

Mark Rothera
PTC Therapeutics (PTCT)

Ranked #1,593 out of 99,137 Corporate Insiders

Profitable Transactions

9 out of 11 Profitable Transactions

Average Return

Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

A breakdown of Mark Rothera's holdings

Insider Roles

PTC Therapeutics
Viracta Therapeutics
President & CEO, Director
Roles that Mark Rothera holds in companies

Most Profitable Insider Trade

PTC Therapeutics
Rating:Informative Buy
Date:Mar 17, 2017 - Mar 17, 2018
The most profitable trade made by Mark Rothera

Mark Rothera's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
PTC Therapeutics
May 25, 2017
Informative Buy
Viracta Therapeutics
Dec 04, 2023
President & CEO, Director
Informative Buy
Jun 05, 2012
Uninformative Buy
List of latest transactions for each holding click on a transaction to see Mark Rothera's performance on stock

Mark Rothera insider profile FAQ

What is the percentage of profitable transactions made by Mark Rothera?
The percentage of profitable transactions made by Mark Rothera is 82%.
    What is the average return per transaction made by Mark Rothera?
    The average return per transaction made by Mark Rothera is 53.40%.
      What stocks does Mark Rothera hold?
      Mark Rothera holds: PTCT, VIRX, AEGR stocks.
        What was Mark Rothera’s latest transaction?
        Mark Rothera latest transaction was an Informative Buy of $49.00K.
          What was Mark Rothera's most profitable transaction?
          Mark Rothera’s most profitable transaction was an Informative Buy of PTCT stock on March 17, 2017. The return on the trade was 233.30%.
            What is Mark Rothera's role in PTC Therapeutics?
            Mark Rothera's role in PTC Therapeutics is CCO.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.